Preclinical News and Research

RSS

COIN hosts ‘Risk vs. Reward: Financing Early-Stage, Emerging Technologies’ roundtable event

The Center of Innovation for Nanobiotechnology (COIN) has announced the upcoming NanoBio Executive Roundtable event to be hosted at The Hawthorne Inn in Winston-Salem, NC on July 14, 2011. This Roundtable will address a significant hurdle to nanobiotechnology development and commercialization—early-stage funding.

29 Jun 2011

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Acetylon Pharmaceuticals, Inc. announced today that it has completed a $27 million Series B Preferred equity investment round of financing.

29 Jun 2011

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Threshold Pharmaceuticals, Inc., today announced the initiation of a Phase 1/2 dose escalation clinical trial of TH-302 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumor (PNET).

29 Jun 2011

Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the year ended March 31, 2011, as well as financial results for the fourth quarter.

29 Jun 2011

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Anacor Pharmaceuticals, the Drugs for Neglected Diseases initiative (DNDi), and SCYNEXIS Inc. today announced the successful completion of pre-clinical studies for the first new oral drug candidate discovered specifically to combat human African trypanosomiasis (HAT), also known as sleeping sickness.

29 Jun 2011

Nuvilex to continue development of acquired live-cell encapsulation technology

Nuvilex, Inc. announced its plans to continue development of the live-cell encapsulation technology obtained with its recent acquisition of SG Austria, to carry out the pancreatic cancer clinical trial, to maintain and expand customers utilizing the encapsulation technology, and to establish itself as an active participant in the stem cell arena. The stem cell market was estimated to be $21.5 billion globally in 2010 and is forecast to reach $63.8 billion by 2015.

29 Jun 2011

U.Va. and Epsilon partner to provide commercial version of computer-based diabetes simulation tool

A computer-based diabetes simulation tool developed by University of Virginia researchers is now commercially available, thanks to a partnership with the Charlottesville-based medical research firm The Epsilon Group. The simulator is the only protocol that has been accepted by the U.S. Food and Drug Administration as an alternative to animal testing of Type 1 diabetes control strategies.

29 Jun 2011

Janssen, Jubilant partner for drug discovery in the field of neuroscience

Jubilant Discovery Services Inc., Bedminster, New Jersey, a Jubilant Life Sciences Company, announced today that it has entered into a drug discovery alliance with Janssen Pharmaceutica N.V., Beerse, Belgium, that will aim to deliver preclinical candidates to Janssen. The alliance is set to span an initial period of 3 years and will focus on multiple targets in the area of neuroscience.

28 Jun 2011

Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.

28 Jun 2011

Genentech, FORMA enter structurally innovative agreement for small molecule cancer program

FORMA Therapeutics announced today that it entered into an agreement granting Genentech, a member of the Roche Group, exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed cancer target.

27 Jun 2011

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it recently initiated a Phase 1 clinical trial of EVP-0962, its potent and selective gamma secretase modulator (GSM), in healthy volunteers.

27 Jun 2011

Flamel, Digna Biotech enter joint development agreement for multiple products

Flamel Technologies SA and Digna Biotech SL today announced that the two companies have entered into a joint development agreement for the pre-clinical and clinical development of multiple products.

27 Jun 2011

Positive results from Stealth's Bendavia Phase I renal impairment study

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, announced today the results of a Phase I renal impairment study with Bendavia.

27 Jun 2011

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

Sanofi announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.

27 Jun 2011

New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced new data from a Phase 1b study of ZGN-433, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed a significant improvement in cardiovascular risk markers in severely obese subjects.

27 Jun 2011

Preclinical News and Research

COIN hosts ‘Risk vs. Reward: Financing Early-Stage, Emerging Technologies’ roundtable event

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Amorfix fiscal 2011 net loss decreases to $3,330,437

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Nuvilex to continue development of acquired live-cell encapsulation technology

U.Va. and Epsilon partner to provide commercial version of computer-based diabetes simulation tool

Janssen, Jubilant partner for drug discovery in the field of neuroscience

Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website

Genentech, FORMA enter structurally innovative agreement for small molecule cancer program

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

Flamel, Digna Biotech enter joint development agreement for multiple products

Positive results from Stealth's Bendavia Phase I renal impairment study

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011

Lithium can prevent aggregation of toxic proteins and cell loss linked with Parkinson's

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

BioMarin to acquire Pfizer's Ireland manufacturing plant

FDA grants Fast Track designation for Repligen's RG3039 to treat Spinal Muscular Atrophy

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics